Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
PPAR Res. 2012;2012:371691. doi: 10.1155/2012/371691. Epub 2012 May 8.
To examine fatty acid accumulation and its toxic effects in cells, we analyzed skin fibroblasts from six patients with mitochondrial trifunctional protein deficiency, who had abnormalities in the second through fourth reactions in fatty acid β-oxidation system. We found free fatty acid accumulation, enhanced three acyl-CoA dehydrogenases, catalyzing the first reaction in the β-oxidation system and being assumed to have normal activities in these patients, and PPARα activation that was confirmed in the experiments using MK886, a PPARα specific antagonist and fenofibrate, a PPARα specific agonist. These novel findings suggest that the fatty acid accumulation and the resulting PPARα activation are major causes of the increase in the β-oxidation ability as probable compensation for fatty acid metabolism in the patients' fibroblasts, and that enhanced cell proliferation and increased oxidative stress due to the PPARα activation relate to the development of specific clinical features such as hypertrophic cardiomyopathy, slight hepatomegaly, and skeletal myopathy. Additionally, significant suppression of the PPARα activation by means of MK886 treatment is assumed to provide a new method of treating this deficiency.
为了研究细胞内脂肪酸的积累及其毒性作用,我们分析了六位患有线粒体三功能蛋白缺陷症患者的皮肤成纤维细胞,这些患者的脂肪酸β-氧化系统第二至第四反应存在异常。我们发现游离脂肪酸的积累、增强了催化β-氧化系统第一反应的三种酰基辅酶 A 脱氢酶,这些酶在这些患者中被认为具有正常的活性,并且证实了 PPARα 的激活,这是使用 PPARα 特异性拮抗剂 MK886 和 PPARα 特异性激动剂非诺贝特进行实验的结果。这些新发现表明,脂肪酸的积累和由此产生的 PPARα 激活是增加β-氧化能力的主要原因,可能是对患者成纤维细胞中脂肪酸代谢的补偿,而由于 PPARα 激活导致的细胞增殖增强和氧化应激增加与特定临床特征的发展有关,如肥厚型心肌病、轻度肝肿大和骨骼肌病。此外,通过 MK886 治疗对 PPARα 激活的显著抑制作用,可能为治疗这种缺陷提供了一种新方法。